Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
IMPACT Therapeutics Inc
InteR Technologies BV
Merck KGaA
Shuttle Pharmaceuticals Inc
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles
Antisense Ri Oligonucleotides to Inhibit ATM for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KU-55933 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-3541 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATM for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-1161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Dormant Products
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Discontinued Products
Serine Protein Kise ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2020: Shuttle Pharmaceuticals awarded a new patent for dual function HDAC molecules for HDAC inhibition and ataxia telangiectasia mutated activation for cancer treatment
May 07, 2019: Xstrahl In Action: ATM inhibitors radiosensitize and improves survival of preclinical brain tumor models
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by IMPACT Therapeutics Inc, 2021
Pipeline by InteRNA Technologies BV, 2021
Pipeline by Merck KGaA, 2021
Pipeline by Shuttle Pharmaceuticals Inc, 2021
Dormant Projects, 2021
Discontinued Products, 2021